NEUROFENCINE Trademark

Trademark Overview


On Thursday, July 29, 2010, a trademark application was filed for NEUROFENCINE with the United States Patent and Trademark Office. The USPTO has given the NEUROFENCINE trademark a serial number of 85096180. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Saturday, June 18, 2011. The NEUROFENCINE trademark is filed in the Pharmaceutical Products category with the following description:

Animal feed additive for use as a nutritional supplement for medical purposes; Animal feed supplements; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Dietary and nutritional supplements; Dietary and nutritional supplements containing agmatine, G-agmatine; Dietary and nutritionally fortified food products adapted for medical use; Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary drink mix for use as a meal replacement; Dietary food supplements; Dietary pet supplements in the form of pet treats; Dietary supplement beverage for healthy nervous system; Dietary supplemental drinks; Dietary supplemental drinks in the nature of vitamin and mineral beverages; Dietary supplements; Dietary supplements also containing agmatine, G-agmatine; Dietary supplements for animals; Dietary supplements for human consumption; Dietary supplements for pets; Dietary supplements for pets in the nature of a powdered drink mix; Feed sup...
neurofencine

General Information


Serial Number85096180
Word MarkNEUROFENCINE
Filing DateThursday, July 29, 2010
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateSaturday, June 18, 2011
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesAnimal feed additive for use as a nutritional supplement for medical purposes; Animal feed supplements; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Dietary and nutritional supplements; Dietary and nutritional supplements containing agmatine, G-agmatine; Dietary and nutritionally fortified food products adapted for medical use; Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary drink mix for use as a meal replacement; Dietary food supplements; Dietary pet supplements in the form of pet treats; Dietary supplement beverage for healthy nervous system; Dietary supplemental drinks; Dietary supplemental drinks in the nature of vitamin and mineral beverages; Dietary supplements; Dietary supplements also containing agmatine, G-agmatine; Dietary supplements for animals; Dietary supplements for human consumption; Dietary supplements for pets; Dietary supplements for pets in the nature of a powdered drink mix; Feed supplements for healthy nervous system; Food supplements; Foods for individuals with special dietary requirements necessitated by medical treatments; Health food supplements; Homeopathic pharmaceuticals for use in the treatment of nervous system damage; Homeopathic supplements; Liquid nutritional supplement; Meal replacement and dietary supplement drink mixes; Medicated supplements for foodstuffs for animals; Medicated supplements for foodstuffs for babies; Natural supplements for treating depression and anxiety; Non-medicated additives for animal feed for use as nutritional supplements; Nutraceuticals for use as a dietary supplement; Nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; Nutritional additives for medical purposes used in foods and dietary supplements for human consumption; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplements; Nutritional supplements in capsule form for dogs; Nutritional supplements in lotion form sold as a component of nutritional skin care products; Ocular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological,gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for thetreatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics,antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of nervous system damage; Pharmaceutical preparations for the treatment and prevention of nervous system damage; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of nervous system damage; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for wounds; Pharmaceutical preparations for treatment and prevention of nervous system; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical products for ophthalmological use; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Powdered nutritional supplement drink mix; Therapeutic pharmaceutical for the treatment of treatment and prevention of nervous system; Vitamins and dietary food supplements for animals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 3, 2010
Primary Code005
First Use Anywhere DateWednesday, January 27, 2010
First Use In Commerce DateWednesday, January 27, 2010

Trademark Owner History


Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressReseda, CA 91335

Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressReseda, CA 91335

Trademark Events


Event DateEvent Description
Monday, June 20, 2011ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Saturday, June 18, 2011ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Saturday, November 20, 2010NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, November 20, 2010NON-FINAL ACTION E-MAILED
Saturday, November 20, 2010NON-FINAL ACTION WRITTEN
Friday, November 12, 2010ASSIGNED TO EXAMINER
Tuesday, August 3, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, August 2, 2010NEW APPLICATION ENTERED IN TRAM